Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 82
Filtrar
1.
Clin Nephrol ; 75(3): 204-11, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21329630

RESUMO

BACKGROUND: There is a paucity of data concerning the risks associated with warfarin in hemodialysis (HD) patients. We compared major bleeding episodes in this group with HD patients not receiving warfarin and with a cohort of non-HD patients receiving warfarin. METHODS: A retrospective review of 141 HD patients on warfarin (HDW), 704 HD patients not on warfarin (HDNW) and 3,266 non-dialysis warfarin patients (NDW) was performed. Hospital admissions for hemorrhagic events and ischemic strokes were examined as was hospital length of stay and blood product use. INR variability was also assessed. RESULTS: The incidence rates for major hemorrhage per 100 patient years was 10.8 in the HDW group as compared to 8.0 in the HDNW (p = 0.593) and 2.1 in the NDW (p < 0.001) groups. Mean units of red blood cell transfusions required was higher in patients on dialysis with no significant difference between HDW and HDNW groups. The risk of ischemic stroke per 100 patient years was 1.7 in the HDW group as compared to 0.7 in the HDNW groups (p = 0.636) and 0.4 in the NDW (p = 0.003). The HDW group had higher inter-measurement INR variability compared to the NDW group (p = 0.034). In patients with atrial fibrillation, HDW group had a higher incidence of ischemic stroke than the NDW group (2.2 versus 0.4 events per 100 patient years; p = 0.024). CONCLUSIONS: This study confirms the higher bleeding risk associated with HD/ESRD but suggests that warfarin use in these patients may not add significantly to this risk. We also demonstrated high rates of ischemic stroke in HD patients despite warfarin use. SUMMARY: Our study compares the frequency of major hemorrhage and secondarily, ischemic stroke in HD patients receiving or not receiving warfarin, with non-HD patients receiving warfarin. The major finding was that frequency of hemorrhage was higher in HD patients receiving warfarin than in non-HD patients receiving warfarin, but not different in HD patients with or without warfarin. A secondary finding was that INR variability was significantly higher in HD patients than non-HD patients on warfarin.


Assuntos
Anticoagulantes/efeitos adversos , Fibrilação Atrial/tratamento farmacológico , Coagulação Sanguínea/efeitos dos fármacos , Isquemia Encefálica/prevenção & controle , Hemorragia/induzido quimicamente , Diálise Renal/efeitos adversos , Acidente Vascular Cerebral/prevenção & controle , Varfarina/efeitos adversos , Idoso , Fibrilação Atrial/sangue , Fibrilação Atrial/complicações , Isquemia Encefálica/etiologia , Transfusão de Eritrócitos , Feminino , Hemorragia/terapia , Hospitalização , Humanos , Coeficiente Internacional Normatizado , Irlanda , Tempo de Internação , Masculino , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Acidente Vascular Cerebral/etiologia
2.
Ir J Med Sci ; 180(2): 429-33, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21046471

RESUMO

BACKGROUND: Steroid therapy is associated with significant morbidity in renal transplant recipients. However, there is concern that steroid withdrawal will adversely affect outcome. METHODS: We report on 241 renal transplant recipients on different doses of corticosteroids at 3 months (zero, ≤ 5 mg/day, > 5 mg/day). Parameters analysed included blood pressure, lipid profile, weight change, new onset diabetes after transplantation (NODAT), allograft survival and acute rejection. RESULTS: Elimination of corticosteroids had no impact on allograft survival at 1 year. There were no cases of NODAT in the steroid withdrawal group compared with over 7% in each of the steroid groups. There were no significant improvements in weight gain, blood pressure control or total cholesterol with withdrawal of steroids before 3 months. CONCLUSIONS: In renal transplant patients treated with tacrolimus and mycophenolate, early withdrawal of steroids does not appear to adversely affect allograft outcome at 1 year. It may result in less NODAT.


Assuntos
Corticosteroides/administração & dosagem , Sobrevivência de Enxerto , Transplante de Rim/imunologia , Corticosteroides/efeitos adversos , Adulto , Diabetes Mellitus/etiologia , Quimioterapia Combinada , Feminino , Seguimentos , Humanos , Imunossupressores/uso terapêutico , Irlanda , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Estudos Retrospectivos , Tacrolimo/uso terapêutico , Adulto Jovem
3.
Ren Fail ; 32(4): 459-63, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20446784

RESUMO

AIM: Encapsulating peritoneal sclerosis (EPS) is arguably the most serious complication of chronic peritoneal dialysis (PD) therapy with extremely high mortality rates. We aimed to establish the rates of EPS and factors associated with its development in a single center. METHODS: We retrospectively reviewed the records of all our PD patients from 1 January 1989 until 31 December 2008. All suspected cases were confirmed at laparotomy. Multifactorial models adjusted for potentially confounding variables such as age and sex. RESULTS: Eleven cases of EPS were identified giving a prevalence rate of 1.98%. Median duration on PD was substantially longer in affected versus unaffected patients (42.5 months versus 13.8 months; p = 0.0002). EPS patients had experienced a mean of 3.54 previous cases of peritonitis (1 infection per year versus 0.71 per year in unaffected patients; p = 0.075). Six patients died (54.5%) due to intra-abdominal sepsis including all five who presented with small bowel obstruction. Three patients had an omentectomy and adhesiolysis performed with a successful outcome. CONCLUSION: Our study reinforces the link between duration on PD and EPS. While mortality was high in our cohort, emerging surgical techniques demonstrate a favorable outcome that can be achieved even in severely affected cases.


Assuntos
Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Fibrose Peritoneal/etiologia , Adulto , Feminino , Humanos , Irlanda/epidemiologia , Falência Renal Crônica/complicações , Falência Renal Crônica/terapia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Diálise Peritoneal Ambulatorial Contínua/mortalidade , Fibrose Peritoneal/mortalidade , Fibrose Peritoneal/terapia , Prevalência , Estudos Retrospectivos , Fatores de Risco , Estatísticas não Paramétricas
4.
Transplant Proc ; 41(9): 3690-2, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19917368

RESUMO

BACKGROUND: Antibody-mediated rejection (AMR) continues to pose a serious challenge in renal transplantation with potentially devastating consequences. Treatment options for this condition include plasmapheresis, high-dose intravenous immunoglobulin (IVIG), plasmapheresis with low-dose IVIG, and the use of rituximab (anti-CD20 chimeric antibody). We previously reported on the short-term outcome of plasmapheresis as a rescue therapy for AMR in our centre. We now report on the long-term follow up. METHODS: Over a 2.5-year study period, 440 cadaveric transplants were performed. AMR developed in 20 (4.5%) patients. Treatment included plasmapheresis and intensification of their immunosuppressive therapy. RESULTS: Excluding two patients who had infarcted their grafts at diagnosis, 18 patients received plasmapheresis treatment for AMR. Of the 18 patients treated, 14 recovered function, two developed graft infarction within a fortnight of starting plasmapheresis, and two patients were withdrawn from treatment. In the 14 who recovered renal function, graft survival was 86% at 12 months. In this study we report on the 5-year follow-up of these AMR-treatment responders. Eleven patients have a functioning graft at 5 years; graft function was stable with a mean serum creatinine of 130 micromol/L at 5 years compared to 123 mumol/L at 1 year. At 5-years follow-up; graft survival was 78% and patient survival 93%. CONCLUSIONS: Little information is available in the literature regarding the long-term outcome of this therapy. This is the first report on the long-term (5-year) follow-up of plasmapheresis as a rescue therapy for AMR.


Assuntos
Rejeição de Enxerto/tratamento farmacológico , Isoanticorpos/sangue , Transplante de Rim/imunologia , Plasmaferese/métodos , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Murinos , Cadáver , Creatinina/sangue , Rejeição de Enxerto/epidemiologia , Rejeição de Enxerto/imunologia , Sobrevivência de Enxerto , Humanos , Imunoglobulinas Intravenosas/uso terapêutico , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Transplante de Rim/mortalidade , Rituximab , Taxa de Sobrevida , Doadores de Tecidos , Resultado do Tratamento
5.
Clin Nephrol ; 72(5): 331-6, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19863874

RESUMO

BACKGROUND: Acute interstitial nephritis (AIN) secondary to trimethoprim-sulfamethoxazole (TMP-SMX) is well documented as a cause of acute renal failure in native kidneys. TMP-SMX is the standard prophylactic agent against pneumocystis carinii (PCP) used in the early post-transplant period, however, it has to date only been indirectly associated with AIN in renal allografts. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: We describe eleven renal transplant patients with acute allograft dysfunction in whom a transplant biopsy demonstrated primary histopathologic features of allergic AIN, all of whom were receiving TMP-SMX in addition to other medications known to cause AIN. RESULTS: All cases occurred within 1 month of transplantation and accounted for 2.12% (11/518) of the total number of transplant biopsies performed during the study period. However, this figure increased to 10.1% (11/109) when those biopsies performed for early allograft dysfunction (< 1 month) were taken into account. After discontinuation of TMP- SMX alone, all patients had an immediate improvement in serum creatinine with excellent long term allograft function - mean improvement of serum creatinine from 465 micromol/l to 136 micromol/l at last follow-up (range 15 - 55 months). CONCLUSIONS: AIN secondary to TMP-SMX, although an uncommon cause of allograft dysfunction over the study period, accounted for over 10% of cases of allograft dysfunction within the first month of transplantation. Therefore, a high degree of clinical suspicion for TMP-SMX-induced AIN is warranted when confronted with early acute allograft dysfunction.


Assuntos
Anti-Infecciosos/efeitos adversos , Transplante de Rim , Nefrite Intersticial/induzido quimicamente , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos , Doença Aguda , Adulto , Idoso , Anti-Infecciosos/uso terapêutico , Creatinina/sangue , Feminino , Humanos , Imunossupressores/uso terapêutico , Rim/patologia , Rim/fisiopatologia , Masculino , Pessoa de Meia-Idade , Nefrite Intersticial/diagnóstico , Nefrite Intersticial/patologia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
6.
Ir J Med Sci ; 178(4): 407-12, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19495831

RESUMO

BACKGROUND: Renal transplantation remains the preferred method of renal replacement therapy in terms of patient survival, quality of life and cost. However, patients have a high risk of complications ranging from rejection episodes, infection and cancer, amongst others. AIMS AND METHODS: In this study, we sought to determine the long-term health outcomes and preventive health measures undertaken for the 1,536 living renal transplant patients in Ireland using a self-reported questionnaire. Outcomes were divided into categories, namely, general health information, allograft-related information, immunosuppression-related complications and preventive health measures. RESULTS: The results demonstrate a high rate of cardiovascular, neoplastic and infectious complications in our transplant patients. Moreover, preventive health measures are often not undertaken by patients and lifestyle choices can be poor. CONCLUSIONS: This study highlights the work needed by the transplantation community to improve patient education, adjust immunosuppression where necessary and aggressively manage patient risk factors.


Assuntos
Comportamentos Relacionados com a Saúde , Nível de Saúde , Transplante de Rim/efeitos adversos , Doenças Cardiovasculares/epidemiologia , Feminino , Fertilidade , Inquéritos Epidemiológicos , Humanos , Terapia de Imunossupressão/efeitos adversos , Infecções/epidemiologia , Irlanda/epidemiologia , Transplante de Rim/imunologia , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Osteoporose/epidemiologia , Medicamentos sob Prescrição , Autorrelato , Fatores de Tempo
7.
Ren Fail ; 30(4): 345-52, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18569905

RESUMO

Renal transplantation is the optimal mode of renal replacement. Improvements in graft survival and acute rejection rates have made these outcomes less useful for prognostication and as end-points in clinical trials; accurate surrogate markers of long-term graft outcome are therefore increasingly important. This study examines the relationship between both serum creatinine (SCr(1 yr)) and MDRD estimated glomerular filtration rate measured at one year (eGFR(MDRD)(1 yr)) as predictors of graft survival. Data on 1,110 patients who received a renal transplant between 1989 and 2005 were extracted from the Irish Renal Transplant Registry. The study group was divided into quartiles of patient numbers according to SCr(1 yr) and eGFR(MDRD)(1 yr). Kaplan-Meier estimates of the primary end-point graft survival were constructed for each quartile. Additionally, a Cox Regression restricted cubic spline model was performed for both eGFR(MDRD)(1 yr) and SCr(1 yr). Both overall graft outcome and outcome censored for death with a functioning graft (CDWFG) were used as endpoints. Cox regression analysis was performed along with tests for the proportionality assumption to compare the predictive value of eGFR(MDRD)(1 yr)and SCr(1 yr). Both eGFR(MDRD)(1yr) and SCr(1 yr) were independently associated with long-term renal transplant survival. eGFR(MDRD)(1 yr) and SCr(1 yr) had similarly strong associations with long-term outcome when the quartile variables were compared using the Bayesian Information Criterion method. The Cox regression restricted cubic spline modeling demonstrated that an eGFR(MDRD)(1 yr) value < 27 mLs/min/1.73 m(2) and a SCr(1 yr) value > 229 micromol/L were associated with poor graft survival.


Assuntos
Creatinina/urina , Taxa de Filtração Glomerular/fisiologia , Falência Renal Crônica/cirurgia , Transplante de Rim/métodos , Adulto , Fatores Etários , Feminino , Seguimentos , Rejeição de Enxerto , Sobrevivência de Enxerto , Humanos , Estimativa de Kaplan-Meier , Falência Renal Crônica/diagnóstico , Testes de Função Renal , Transplante de Rim/efeitos adversos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Modelos de Riscos Proporcionais , Sistema de Registros , Estudos Retrospectivos , Medição de Risco , Fatores Sexuais , Estatísticas não Paramétricas , Fatores de Tempo , Resultado do Tratamento
8.
Euro Surveill ; 12(4): E7-8, 2007 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-17991388

RESUMO

In April 2005, a case of reactivation of hepatitis B virus (HBV) infection occurred in a patient undergoing haemodialysis in an Irish hospital. This incident potentially affected patients attending hospitals throughout the country, so a national incident team was set up coordinate the response to the incident.A total of 306 dialysis patients, attending 17 different dialysis centres (14 in Ireland), were identified as having been potentially exposed to HBV as a result of this incident. A programme of HBV serological testing and HBV vaccination was instituted. There was no evidence that any patient acquired HBV infection as a result of cross-infection from the index patient, although 11 patients (3.6%) had evidence of past infection (anti-HBc positive, HBsAg negative). The majority of patients in this cohort were of unknown HBV vaccination status (62.7%), 13.4% were fully vaccinated, 4.6% partially vaccinated and 15.7% unvaccinated. Of 239 tested for anti-HBs, 183 (76.6%) had a titre <10 mIU/ml. Local incidents in dialysis units can have national implications due to the frequent patient transfer between units. This incident highlighted serious deficiencies in current structures and practices, and a lack of appropriate guidelines. However, there were positive outcomes from this incident. The majority of Irish dialysis patients have now been vaccinated against HBV, and lessons learned have been used to develop national guidelines on HBV vaccination and testing and on the management of incidents of blood-borne viral infections in dialysis units.


Assuntos
Infecção Hospitalar/epidemiologia , Surtos de Doenças/estatística & dados numéricos , Hepatite B/epidemiologia , Vigilância da População , Diálise Renal/estatística & dados numéricos , Medição de Risco/métodos , Surtos de Doenças/prevenção & controle , Hepatite B/prevenção & controle , Humanos , Incidência , Irlanda/epidemiologia , Fatores de Risco
9.
Kidney Int ; 69(3): 504-11, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16395262

RESUMO

Previous studies suggested that membranoproliferative glomerulonephritis (MPGN) type II has a worse renal survival and an unacceptable risk of recurrence post transplantation. We hypothesised that other factors may determine this risk. We analysed all cases (n=70) of MPGN diagnosed by renal biopsy in Ireland from 1972 to 1995. We used Cox regression analysis to determine factors that were independently predictive of renal failure. MPGN II had more crescent formation and mesangial proliferation (P<0.05). Mean follow-up duration was 13.8 years, during which time 41 (58.6%) developed end-stage renal failure (ESRF). The median time to ESRF was 8.3 years (95% confidence interval 5.7-10.9) and 5-, 10-, and 20-year probabilities of ESRF were 32, 54, and 70%, respectively. Multivariate analysis revealed that severity of interstitial fibrosis (P<0.05), crescent formation (P<0. 01) and mesangial proliferation (P<0.05) were independently associated with ESRF. Decade of diagnosis, age, MPGN type, and creatinine or complement level at baseline did not predict renal survival in this model. In 21 (49%) of the 43 renal transplants, MPGN recurred. Younger age at initial diagnosis (P<0.01) and the presence of crescents on the original biopsy (P<0.005) were independently associated with recurrence on multivariate analysis. MPGN type was not associated with recurrence in this model. Contrary to previous reports, after controlling for crescent formation, MPGN II was not associated with more ESRF or recurrence in the allograft. It is therefore the more aggressive glomerular changes associated with MPGN II, rather than the disease type per se, that determine outcome.


Assuntos
Glomerulonefrite Membranoproliferativa/patologia , Glomerulonefrite Membranoproliferativa/fisiopatologia , Transplante de Rim , Adolescente , Adulto , Fatores Etários , Idoso , Criança , Pré-Escolar , Estudos de Coortes , Feminino , Glomerulonefrite Membranoproliferativa/cirurgia , Humanos , Rim/patologia , Rim/fisiopatologia , Falência Renal Crônica/patologia , Falência Renal Crônica/fisiopatologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Recidiva , Análise de Regressão , Estudos Retrospectivos , Fatores de Risco , Índice de Gravidade de Doença , Análise de Sobrevida , Sobrevivência de Tecidos , Resultado do Tratamento
10.
Ir J Med Sci ; 174(2): 9-13, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16094906

RESUMO

BACKGROUND: The aim of this paper was to evaluate patient and kidney graft survival rates in renal transplant recipients and compare the outcomes between the different patient age groups. METHODS: A retrospective review of all adult renal transplants performed at Beaumont Hospital between the years 1986-2001 was carried out. Patients were defined as 'elderly' if they were 65 years of age or older and 'younger' if less than 65 years at the time of transplantation. Patient and transplant graft survival rates were analysed for each age group. RESULTS: Data were analysed on 1462 'younger' patients and 105 'elderly' renal transplant recipients. Estimated patient survival at 1, 5 and 10 years were 96%, 87% and 74% in the younger patient group compared to 85%, 59% and 33% in the elderly group. The adjusted graft survival rates (adjusted for death due to other causes and with a functioning graft in situ) for the younger group were 89%, 77% and 64% at one, five and ten years respectively, while for the elderly group, adjusted one, five and ten year survival rates were 89%, 83% and 70% respectively. CONCLUSIONS: Although the elderly have a shorter life expectancy than the younger population they do benefit from renal transplantation similar to the younger recipients.


Assuntos
Sobrevivência de Enxerto , Transplante de Rim/mortalidade , Transplante/mortalidade , Resultado do Tratamento , Fatores Etários , Idoso , Feminino , Humanos , Irlanda/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Análise de Sobrevida
11.
Ir J Med Sci ; 174(1): 42-8, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15868889

RESUMO

BACKGROUND: Since the introduction of renal transplantation in the Republic of Ireland in 1964, the number of transplants performed annually has increased from single figures in the 1960s to the current rate of approximately 130 renal transplants per year. Improvements in graft and patient outcomes have been associated with the introduction of the immunosuppressive agent Cyclosporin (CSA) in the mid 1980s. AIMS: The aim of this study was to examine trends in outcomes and factors that influence outcomes for adult kidney transplantation from 1986 to 2001. METHODS: All adult cadaveric kidney transplantations carried out between 1986 and 2001 were included. We separated the transplanted grafts and patients into four time periods; 1986-1989, 1990-1993, 1994-1997, 1998-2001. Graft and patient survival outcomes were compared for the different periods. RESULTS: The one-year kidney graft survival rate increased from 82% during 1986-1989 to 86% during 1998-2001. Patient survival over the four time periods studied has remained stable at approximately 95% at one year. CONCLUSION: We report a significant improvement in kidney graft outcomes over the past 16 years. Patient survival has remained relatively stable during this period.


Assuntos
Cadáver , Transplante de Rim/mortalidade , Análise de Sobrevida , Resultado do Tratamento , Adulto , Ciclosporina/uso terapêutico , Feminino , Teste de Histocompatibilidade , Humanos , Imunossupressores/uso terapêutico , Irlanda/epidemiologia , Transplante de Rim/imunologia , Transplante de Rim/estatística & dados numéricos , Masculino , Cuidados Pós-Operatórios , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Fatores de Risco , Fatores de Tempo
12.
Ir J Med Sci ; 173(2): 82-4, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15540708

RESUMO

BACKGROUND: The impact of hepatitis C virus (HCV) infection in renal transplant patients is controversial and there are no data on the outcome of renal transplantation in this sub-group of Irish patients. AIM: To examine the outcome of renal transplantation in patients with hepatitis C. METHODS: We examined the outcome of first grafts from renal transplant patients with hepatitis C antibody positive and compared them to a control group. During this period, 24 HCV positive patients received 33 grafts. All were treated with standard immunosuppression. RESULTS: Graft survival rate was less in the HCV positive cases (p=0.0087). Graft survival at 1 year was 75% in the HCV positive group versus 85% in the HCV negative group, 40% versus 62% at 5 years and 14% compared with 40% at 10 years. Patient survival was similar in both groups (p=0.78). Patient survival at 1 year was 96% versus 94%, 87% versus 80% at 5 years and 70% in both groups at 10 years. CONCLUSION: In the Irish renal transplant population, the presence of hepatitis C antibodies, before or after transplantation is associated with worse long-term graft, but not patient survival.


Assuntos
Hepatite C/complicações , Falência Renal Crônica/cirurgia , Transplante de Rim/mortalidade , Adulto , Estudos de Casos e Controles , Ensaio de Imunoadsorção Enzimática , Feminino , Sobrevivência de Enxerto/imunologia , Hepatite C/epidemiologia , Hepatite C/imunologia , Anticorpos Anti-Hepatite C/imunologia , Humanos , Irlanda/epidemiologia , Falência Renal Crônica/complicações , Transplante de Rim/imunologia , Masculino , Sistema de Registros , Estudos Retrospectivos , Fatores de Risco , Análise de Sobrevida , Transplante Homólogo/imunologia
13.
Br J Surg ; 90(9): 1137-41, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12945083

RESUMO

BACKGROUND: There are emerging data that simultaneous pancreas-kidney transplant (SPK) prolongs life compared with kidney transplant alone (KTA) in type 1 diabetics with end-stage renal disease. This study was a retrospective comparison of SPK with KTA in patients with type 1 diabetes. METHODS: Between 1 January 1992 and 30 April 2002, 101 patients with type 1 diabetes were transplanted. Fifty-one of these patients received a KTA and 50 had a SPK. All patients underwent coronary angiography with surgical correction of any coronary artery disease before being listed. All patients who underwent SPK received quadruple immunosuppressive therapy consisting of antilymphocyte globulin, calcineurin inhibitor (tacrolimus or cyclosporin), azathioprine and steroids. Those who underwent KTA received calcineurin inhibitor (tacrolimus or cyclosporin), azathioprine and steroids. RESULTS: Patient survival at 1, 3, 5 and 8 years was 96, 93, 89 and 77 per cent respectively after SPK, and 93, 75, 57 and 47 per cent respectively after KTA (P = 0.018 at 8 years). CONCLUSION: The addition of pancreatic transplantation prolongs life in type 1 diabetic patients with renal failure compared with renal transplantation alone.


Assuntos
Diabetes Mellitus Tipo 1/cirurgia , Nefropatias Diabéticas/cirurgia , Falência Renal Crônica/cirurgia , Transplante de Rim/métodos , Transplante de Pâncreas/métodos , Adulto , Idoso , Diabetes Mellitus Tipo 1/mortalidade , Nefropatias Diabéticas/mortalidade , Feminino , Sobrevivência de Enxerto , Humanos , Falência Renal Crônica/mortalidade , Transplante de Rim/mortalidade , Masculino , Pessoa de Meia-Idade , Transplante de Pâncreas/mortalidade , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento
14.
Ir J Med Sci ; 171(1): 42-3, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-11993595

RESUMO

BACKGROUND: Peritonitis resulting from peritoneal dialysis (PD) remains a serious cause of morbidity and even mortality among dialysis patients. AIM: To highlight the danger of antibiotic resistance in patients on dialysis who have received multiple courses of antibiotics. METHODS: Two cases are reported in which the patients developed peritonitis resistant to vancomycin. CONCLUSIONS: Multi-drug resistance is a growing danger. It is imperative to use the most appropriate antibiotics in the proper dosage. If infections persist, early removal of the catheters is essential. The use of antibiotics in PD patients needs to be limited. Sensitivity patterns of the cultured organisms must be monitored regularly as the lack of vigilance may help accelerate the development of the so-called 'super bug' resistant to all antibiotics.


Assuntos
Enterococcus faecium , Infecções por Bactérias Gram-Positivas/tratamento farmacológico , Diálise Peritoneal/efeitos adversos , Peritonite/tratamento farmacológico , Peritonite/etiologia , Infecções Estafilocócicas/tratamento farmacológico , Infecções Estafilocócicas/etiologia , Staphylococcus epidermidis , Resistência a Vancomicina , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade
15.
J Epidemiol Community Health ; 56(5): 389-93, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-11964438

RESUMO

STUDY OBJECTIVE: The purpose of the study was to determine the relations between maternal work, ambulatory blood pressure in mid-pregnancy, and subsequent pregnancy outcome. DESIGN: Data were studied on 933 healthy normotensive primigravidas who had been enrolled into a study on the predictive value of ambulatory blood pressure measurement performed between 18 and 24 weeks gestation. They were classified into three groups depending on whether they were at work (working group, n=245), not working (not working group, n=289), or normally employed but chose not to work (ENK group, n=399), on the day monitoring was performed. SETTING: The Rotunda Hospital (a large maternity hospital), Dublin, Ireland. MAIN RESULTS: Adjusted for age, body mass index, smoking, drinking, and marital status, women at work had higher mean daytime systolic (p<0.01) and diastolic (p<0.01) and 24 hour systolic pressures (p=0.03) compared with those not working. The rate of subsequent development of pre-eclampsia was significantly higher (odds ratio 4.1, 95% CI 1.1 to 15.2, p=0.03) among those at work compared with those not working. The association between pre-eclampsia and maternal work remained significant (odds ratio 5.5, 95% CI 1.1 to 27.8, p=0.04) even after allowing for the confounding factors of age, smoking, body mass index, and marital status. When daytime systolic and diastolic blood pressure were added to the regression analysis the risk ratios for pre-eclampsia remained high but did not quite reach statistical significance (odds ratio 4.7, 0.90 to 24.8, p=0.066). Birth weight and placental weight were not predicted by work status or blood pressure. CONCLUSIONS: A significant independent relation was found between maternal work and ambulatory blood pressure levels in mid-pregnancy. In addition, it was found that maternal work was significantly associated with the subsequent development of pre-eclampsia


Assuntos
Monitorização Ambulatorial da Pressão Arterial , Emprego , Pré-Eclâmpsia/etiologia , Complicações Cardiovasculares na Gravidez/etiologia , Adulto , Feminino , Humanos , Razão de Chances , Valor Preditivo dos Testes , Gravidez , Resultado da Gravidez , Segundo Trimestre da Gravidez , Prognóstico
16.
Ren Fail ; 23(5): 705-13, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11725917

RESUMO

OBJECTIVE: We undertook this study to evaluate the incidence and outcome of HELLP in Irish patients. In addition, duration and trends of the abnormal laboratory results were studied. STUDY DESIGN: This prospective observational study screened 12068 pregnant women between January 1995 and March 1997. Any pregnant woman with hypertension, proteinuria, thrombocytopenia or anemia was monitored for hemolysis and elevated liver transaminases, from the time of recruitment till six weeks postpartum or resolution. RESULTS: Thirteen of 12068 pregnant women (0.11%) developed HELLP. All had hypertension and 84.6% had proteinuria. Delivery was the only factor found to terminate the syndrome. Acute renal dysfunction was noted in 53.8% but none required dialysis. Laboratory parameters stabilized by the sixth postpartum day. Fetal mortality was 1 out of 14. There were no maternal deaths. CONCLUSIONS: HELLP syndrome is a rare but potentially serious complication of pregnancy. Correlation with laboratory data and early intervention are vital in achieving a favorable outcome for both mother and fetus.


Assuntos
Morte Fetal/epidemiologia , Síndrome HELLP/diagnóstico , Síndrome HELLP/epidemiologia , Resultado da Gravidez , Adulto , Estudos de Coortes , Feminino , Idade Gestacional , Humanos , Incidência , Irlanda/epidemiologia , Testes de Função Hepática , Gravidez , Estudos Prospectivos , Fatores de Risco , Índice de Gravidade de Doença
17.
Nephrol Dial Transplant ; 16(11): 2194-200, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11682667

RESUMO

BACKGROUND: Despite the US Dialysis Outcome Quality Initiative )DOQI( guidelines, for various reasons, increasing numbers of end-stage renal disease patients are becoming dependent on cuffed haemodialysis catheters (HCs) for chronic haemodialysis access. Their use is complicated by frequent failure due to thrombosis and catheter-related sepsis. In our unit, all HCs are put in place by the radiology department. METHODS: In a prospective study we looked at the outcome of all HCs over a three-year period, during which time 573 consecutive HCs were placed in 336 patients. Each line was followed individually until it was removed or until the end of the study. RESULTS: In a survival analysis of those HCs removed following HC failure, HC half-life was 312 days and one-year HC survival was 47.5%. The most frequent indications for HC removal were non-function (36.6%), clinical suspicion of line sepsis (16.4%) and patient death (14.4%). Using a Cox proportional hazards model, catheter number in a given patient and the presence of diabetes mellitus were found to be independent predictors of HC failure. The total incidence of HC-related sepsis was 1.3 episodes/1000 catheter days. The probability of developing bacteraemic HC-related sepsis was 27.5% at one year. CONCLUSIONS: Less than half of the HCs were removed electively because of availability of a more permanent mode of renal replacement, thereby illustrating the level of dependence that has developed on them as permanent access. Consequently, their limitations (infection and malfunction) are placing an ever increasing burden on the healthcare services.


Assuntos
Cateteres de Demora/efeitos adversos , Diálise Renal/instrumentação , Remoção de Dispositivo , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Prospectivos , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/etiologia , Análise de Sobrevida , Fatores de Tempo
18.
Transpl Int ; 14(2): 108-10, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11370163

RESUMO

We report on the successful use of kidneys procured from a donor with HELLP syndrome. The use of organs from a donor with HELLP syndrome has not been reported previously, perhaps because of the renal complications associated with it. Both recipients have been doing well since renal transplantation, with immediate graft function and acceptable graft function at 2 years of follow-up. In view of the continuing shortage of cadaveric kidneys for transplantation, this report highlights how organs from "marginal" donors should not be discarded without worthy consideration.


Assuntos
Síndrome HELLP , Transplante de Rim , Doadores de Tecidos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Gravidez , Transplante Homólogo
19.
Am J Kidney Dis ; 36(6): 1135-9, 2000 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11096037

RESUMO

Ultrasound dilution technology is emerging as the standard for measuring access recirculation and blood flow in hemodialysis patients. In temporary dialysis catheters, studies using the traditional two-needle urea method have suggested that short femoral catheters are associated with an unacceptably high degree of recirculation. This problem has never been assessed using ultrasound dilution technology. We performed a prospective observational study of consecutive patients undergoing dialysis through a temporary catheter. Measurements were made on 49 catheters; 10 catheters were excluded because poor flow necessitated reversal of the dialysis ports. Thirty-nine catheters in 33 patients were included in this analysis, of which 26 catheters were located in the femoral vein, and 13 catheters, in the internal jugular vein. Dialyzer blood flow was adjusted to give an ultrasonic flow rate of 250 mL/min (actual mean blood flow, 234.3 mL/min; 95% confidence interval [CI], 228 to 241). Overall mean recirculation rate was 8.9% (95% CI, 4.8 to 13.0). Multivariate analysis showed catheter location and length to be independent predictors of recirculation. Blood flow (within the range tested), duration into dialysis, time since catheter insertion, cardiac rhythm, and catheter type had no significant effect on recirculation rates. Recirculation in femoral catheters (13.1%) was significantly greater than that in internal jugular catheters (0.4%; P: < 0.001). Femoral catheters shorter than 20 cm had significantly greater recirculation (26.3%) than those longer than 20 cm (8.3%; P: = 0.007). We conclude that temporary femoral catheters shorter than 20 cm are associated with increased recirculation rates. In addition, when dialysis dose delivery is a priority, locating the temporary catheter in the internal jugular vein is an advantage.


Assuntos
Cateterismo Periférico/métodos , Cateteres de Demora/efeitos adversos , Hemodinâmica/fisiologia , Técnicas de Diluição do Indicador , Diálise Renal/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Soluções para Diálise/administração & dosagem , Feminino , Veia Femoral/fisiologia , Hemorreologia/métodos , Humanos , Veias Jugulares/fisiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Estudos Prospectivos , Diálise Renal/normas , Cloreto de Sódio , Ultrassonografia
20.
Ir Med J ; 93(3): 82-4, 2000 May.
Artigo em Inglês | MEDLINE | ID: mdl-10967854

RESUMO

The population of immunosuppressed patients is growing rapidly because of the HIV epidemic and the rapid expansion in transplant medicine. These patients may present to a variety of clinical specialties with seemingly innocuous infections. We present here the first Irish case of primary cryptococcal cellulitis. The patient was a 62-year old renal transplant recipient and was immunosuppressed with Cyclosporine, Azathioprine and Prednisolone. He presented with an apparent bacterial cellulitis on the dorsum of the hand that had failed to respond to a 3-week course of oral antibiotics. There was no clinical evidence of systemic infection. There was tissue necrosis present and the area was debrided surgically. Histological examination of debrided tissue revealed necrotic granulomata and budding yeast-like organisms. Cryptococcus neoformans was cultured from this specimen. The patient was treated with oral fluconazole 400 mg daily for 6 weeks with complete healing of the infected area and no evidence of recurrence after 12 months of follow up. This case emphasises the need for a high index of suspicion for atypical infection in the immunocompromised patient.


Assuntos
Criptococose/diagnóstico , Dermatomicoses/diagnóstico , Hospedeiro Imunocomprometido , Antifúngicos/uso terapêutico , Criptococose/microbiologia , Criptococose/terapia , Cryptococcus/isolamento & purificação , Dermatomicoses/microbiologia , Dermatomicoses/terapia , Fluconazol/uso terapêutico , Humanos , Transplante de Rim , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Pele/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA